MARYLAND FILES SUIT AGAINST GLAXOSMITHKLINE OVER DIABETES DRUGS

     (The following press release from the Maryland Attorney General's Office 
was received by e-mail and was reformatted. The sender verified the statement.) 
MARYLAND ATTORNEY GENERAL
Douglas F. Gansler
Katherine Winfree, Chief Deputy
John B. Howard, Jr., Deputy 
News Release 
Attorney General Gansler Files Suit Against GlaxoSmithKline, LLC 
Popular diabetes medications Avandia, Avandamet and Avandaryl alleged to be 
unsafe and deceptively marketed to consumers 
Prescription drugs in question dramatically increase chance of heart attack 
Baltimore, MD (February 20, 2013) - Attorney General Douglas F. Gansler 
announced today that Maryland has filed suit against GlaxoSmithKline, LLC over 
that company's misleading marketing of the prescription drugs Avandia, 
Avandamet and Avandaryl. These medications are used to treat diabetes. The 
lawsuit alleges that GlaxoSmithKline touted the drugs as superior to other 
diabetes medications even though they were not, in fact, better at treating the 
disease. 
"GlaxoSmithKline has put diabetes patients at serious risk with misleading 
claims over the safety and efficacy of these drugs," said Attorney General 
Gansler. "We want consumers to know the facts so they can protect themselves 
and we seek to recover the costs of this deceptive behavior." 
The lawsuit also alleges that the company withheld data showing that these 
drugs dramatically increase a patient's chances of suffering a heart attack or 
other serious adverse events. Despite its knowledge of these risks, 
GlaxoSmithKline promoted the drug as safe for use. 
Almost nine percent of Maryland's citizens are diabetic. The State spent more 
than $38 million on Avandia, Avandamet and Avandaryl through the State Employee 
Prescription Drug Plan, the State Retiree Prescription Drug Plan, the Medical 
Assistance Program and other State health care programs.  The State has and 
will continue to incur costs for additional medical costs incurred by those who 
took Avandia and suffered adverse events. 
The lawsuit seeks to recover for the State both the cost of purchasing Avandia 
and the cost of the additional health care costs incurred. 
For a redacted version of the complaint filed under seal by order of the court 
visit: 
http://www.oag.state.md.us/Press/Avandia_complaint_2013_02_20.pdf 
CONTACT: 
David Paulson - 410-576-6357
dpaulson@oag.state.md.us 
Alan Brody - 410-576-6956
abrody@oag.state.md.us  
(kgt)NY